RxDoctor Payments DataLook up a doctor →

Allison Turner

Nurse Practitioner · Houston, TXNPI 1023456076

Payments from drug & device makers

$37,103in general payments, 2019–2025

Across 451 payments — averaging $82.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$13K
  • Omnia Medical, LLC$11K
  • Biotronik NRO, Inc.$4K
  • Abbott$1K
  • Medtronic$1K
  • Spinal Simplicity, LLC$779
  • plus $4K from 32 others

What the payments were for

  • Consulting fees$11,45031%
  • Speaking & faculty fees$14,47739%
  • Travel & lodging$1,8105%
  • Food & beverage$9,33925%
  • Education$270%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,103 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$91,963
Medicare patients
203
Services billed
1,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$53,964
BelbucaBuprenorphine Hcl25$21,112
OzempicSemaglutide16$16,962
UbrelvyUbrogepant11$14,172
MounjaroTirzepatide12$12,602
BotoxOnabotulinumtoxina11$12,347
Buprenorphine43$11,580
ZtlidoLidocaine14$7,036
Gabapentin495$5,823
Acetaminophen-CodeineAcetaminophen With Codeine231$5,370
Lidocaine31$5,316
Pregabalin223$4,665
Tramadol Hcl ErTramadol Hcl49$4,642
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,999
Tizanidine Hcl320$2,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$129$53,96451 claims
AbbVieUbrelvy, Botox$760$26,51922 claims
Collegium Pharmaceutical, Inc.Belbuca$581$21,11225 claims
Lilly USA, LLCMounjaro$137$12,60212 claims
Scilex Pharmaceuticals Inc.Ztlido$351$7,03614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →